Skip to content

Imbria Pharmaceuticals, Inc.

Boston, Massachusetts

Phase II

What changed

Phase II trial registered: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

8mo agoTrial registeredNov 10, 2025Source filing (opens the source filing in a new tab)

Momentum

45no change

Momentum 45 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources